CA-SENSEFORTH.AI
12.8.2021 11:32:07 CEST | Business Wire | Press release
Conversational AI leader Senseforth.ai today announced a $14 million investment from Fractal (fractal.ai ), a global provider of artificial intelligence and analytics solutions to Fortune 500® companies. This investment will help Senseforth.ai scale and expand its footprint across Fractal’s clients globally. This investment also strengthens Fractal's conversational AI offerings as it advances on its mission to power every human decision in the enterprise.
Senseforth.ai’s patented and award winning zero-code platform A.ware automates customer experience across digital touchpoints for global enterprises. It is estimated that by 2022, 30% of customer experiences will be handled by conversational AI, up from 3% in 2017. A.ware makes it easy to build, train, deploy, and scale conversational AI solutions to drive revenue, reduce costs and increase operational efficiency.
Shridhar Marri, CEO and Co-Founder of Senseforth said, “This strategic investment creates a new growth blueprint for Senseforth.ai. We are thrilled to deliver on our vision 'to make technology humanlike', enabling continuous Human-AI interaction and transforming complex business processes.” He added, “We can now scale talent, accelerate growth, make more investments in R&D, and create incredible value for our clients.”
Announcing the strategic investment, Fractal’s Co-Founder, Group Chief Executive and Vice Chairman, Srikanth Velamakanni said, “Senseforth.ai’s founders Shridhar, Krishna and Ritesh have built a great team and a robust platform that’s deployed at scale with marquee clients like HDFC Bank. Senseforth’s technology is ahead of the competition, especially as evidenced by their performance benchmark on the leaderboard of Stanford Question Answering Dataset (SQuAD) 2.0.” Srikanth added, “We are excited to partner with the Senseforth.ai team to contribute to their next phase of growth.”
“We are inspired by Senseforth.ai’s work with the government of India to remove technology barriers in accessing citizen services for 700 million internet users through conversational AI. We are delighted to partner with Senseforth and expand conversational AI solutions to our clients,” said Pranay Agrawal, Fractal’s Co-founder and Chief Executive Officer.
Krishna Kadiri, Chief AI Officer and Co-Founder of Senseforth said, “Senseforth has a robust R&D and innovation culture and has already made its mark in the global ML benchmarks. This investment will help us enhance our deep learning capabilities and embed advanced cutting-edge research into A.ware.”
Don Vadakan, Chief Sales Officer at Fractal said, “Senseforth’s industry agnostic, multi-experience AI platform will drive next-generation digital solutions. We are excited to deliver powerful use cases across industries for both large and mid-size enterprises with A.ware from Senseforth.”
Ritesh Radhakrishnan, CTO, and Co-Founder of Senseforth said, “At Senseforth.ai, we have built A.ware, one of the most powerful and comprehensive Conversational AI Platforms in the market today. A.ware is already automating billions of conversations for enterprises across the world. This investment will help us further strengthen our technology foundation and scale our platform and products to become the undisputed market leader in the Conversational AI space.”
About Senseforth.ai
Senseforth.ai is a Conversational AI platform that enables automated human-like conversations at scale, between organizations and people. Founded with a vision to “make technology humanlike”, Senseforth.ai helps businesses acquire, engage and assist customers using AI-powered bots. As a preferred partner of choice for enterprises in North America, Europe and APAC, Senseforth.ai has implemented 100+ solutions that handle millions of conversations every month and has been recognized as a ‘Cool Vendor’ in Conversational AI Platforms in 2020 by Gartner, For more information, visit www.senseforth.ai
About Fractal
Fractal is one of the leading providers of AI and analytics globally to the world's most admired Fortune 500® companies. Fractal's mission is to power every human decision in the enterprise by bringing AI, engineering, and design to solve some of the world’s toughest problems.
Fractal's products include Qure.ai, to assist radiologists in making better diagnostic decisions; Crux Intelligence, to assist CEOs, and senior executives make better tactical and strategic decisions; Theremin.ai, to improve investment decisions; Eugenie.ai, to find anomalies in high-velocity data; and Samya.ai to drive next generation enterprise revenue growth management.
Fractal has more than 2,800 employees across 16 global locations, including the United States, UK, Ukraine, India, Singapore and Australia. Fractal has consistently been rated among India's best companies to work for, by The Great Place to Work® Institute; featured as a leader in the Customer Analytics Service Providers Wave™ 2021, Specialized Insights Service Providers Wave™ 2020 & Computer Vision Consultancies Wave™ 2020, by Forrester Research; and recognized as an "Honorable Vendor" in 2021 Magic Quadrant™ for data & analytics by Gartner. For more information visit fractal.ai.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210812005361/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom